Company intelligence / Profile preview

Embark Biotech

Copenhagen, Denmark

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Embark Biotech is a Danish clinical-stage biotechnology company focused on developing novel treatments for obesity and related cardiometabolic diseases. Spun out from the University of Copenhagen in 2017, the company specializes in identifying new targets that increase energy expenditure and improve insulin sensitivity. Its lead program targets GPR3, a receptor that stimulates fat burning and thermogenesis. In August 2023, Embark Biotech was acquired by Novo Nordisk to bolster its obesity and diabetes pipeline, while a new independent entity, Embark Laboratories, was established to continue early-stage discovery research.

Therapeutic areas: CardiovascularEndocrinologyGastroenterology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Novo Nordisk

Beyond the preview

Go deeper on Embark Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embark Biotech.

Explore the full profile